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Migration of cutaneous dendritic cells is essential for
the induction of primary immune responses.
Chemotaxis plays an important part in guiding
migrating cells through the skin. Therefore, we
investigated the in¯uence of interleukin-16, a potent
chemoattractant, on the migratory properties of
cutaneous dendritic cells. Interleukin-16 added to
murine and human skin explant cultures, enhanced
emigration of Langerhans cells as well as dermal
dendritic cells out of the skin. In contrast to tumor
necrosis factor-a, intradermally injected interleukin-
16 did not reduce the density of Langerhans cells
suggesting a chemotactic rather than a mechanistic
migration-inducing effect of interleukin-16. In sup-
port of these ®ndings, the known migration-promot-
ing effect of tumor necrosis factor-a in skin explant
cultures could be neutralized by anti-interleukin-16
antibody and vice versa, indicating different but
cooperative ways of action for both cytokines. In
whole skin explant cultures blocking of the inter-
leukin-16 effect was also achieved with a monoclonal
antibody against CD4, the receptor for interleukin-
16. In contrast, in cultures of murine epidermis
alone no blocking by anti-CD4 became obvious and
in CD4-de®cient mice Langerhans cell migration in
response to interleukin-16 was maintained. This sug-
gests that another receptor for interleukin-16 might
be operative for Langerhans cells in the mouse epi-
dermis. Finally, we detected interleukin-16-positive
cells in the dermis of skin explants, tumor necrosis
factor-a-treated and contact allergen-treated skin.
Taken together, it seems likely that locally secreted
interleukin-16 might serve to enhance the migration
of cutaneous dendritic cells and optimize the
response to foreign antigen encountering the skin.
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A
s skin is the ®rst place to encounter antigen it needs a
well-functioning immune defense to act immediately
against penetrating pathogenic agents. Dendritic cells
(DC) of the skin (Langerhans cells and dermal DC),
as sentinels in the peripheral tissues, have the capacity
to take up and process cutaneously applied antigen and present
immunogenic peptides on their cell surface. As professional
antigen-presenting cells they are able to migrate from peripheral
sites to the draining lymph nodes where they ef®ciently stimulate
resting or memory antigen-speci®c T cells (Schuler et al, 1997;
Banchereau and Steinman, 1998; Romani et al, 2001).
The most commonly used system to study DC migration from
skin to lymph nodes is the murine contact hypersensitivity model.
Upon application of contact sensitizers, major histocompatibility
complex (MHC) class II positive cells migrate out of the skin into
regional lymph nodes (Botham et al, 1987; Macatonia et al, 1987).
A proportion of those contain Birbeck granules and seem to be
Langerhans cells. Emigrated cells can sensitize naive T cells in
syngeneic recipients (Kripke et al, 1990). Larsen et al (1990) and our
group (Ortner et al, 1996) have established and re®ned a skin
explant culture that is a useful tool to de®ne further the migratory
pathways of cutaneous DC. At the onset of the cultures Langerhans
cells and dermal DC start to migrate. In the epidermis the
Langerhans cells downregulate E-cadherin expression and loosen
their connections to the surrounding keratinocytes (Tang et al,
1993). After passage of the basement membrane the emigrating DC
invade the lymphatic vessels in the dermis and end up in the culture
medium (Lukas et al, 1996; Weinlich et al, 1998).
The emigration of cutaneous DC is regulated by in¯ammatory
mediators, such as lipopolysaccharide (LPS), tumor necrosis factor
(TNF)-a and interleukin (IL)-1b. After subcutaneous application
of LPS and TNF-a a loss of Langerhans cells in the epidermis, and
lymph vessels ®lled with emigrating DC became visible (Roake
et al, 1995). Similar to that, Cumberbatch et al (1997) showed that
TNF-a and IL-1b injected intradermally could reduce the number
of remaining Langerhans cells in the epidermis and increase the
number of DC in draining lymph nodes. We have recently
con®rmed and further dissected the effects of TNF-a and IL-1b in
the murine skin explant model (Stoitzner et al, 1999). Furthermore,
it was demonstrated that in response to the application of contact
allergens on to murine and human skin, the mRNA in epidermal
cells for IL-1b was detected after 15 min, and that of TNF-a and
IL-1a 45 min later (Enk et al, 1993; Rambukkana et al, 1996).
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There is evidence that chemokines, such as macrophage
in¯ammatory protein-3b, MIP-3b/CCL19 (Kellermann et al,
1999), secondary lymphoid tissue chemokine, SLC/CCL21
(Saeki et al, 1999), and anti-in¯ammatory cytokines, such as IL-
10 (Wang et al, 1999), can interfere in this emigration process in a
regulatory way. IL-16 is synthesized and released by CD8+ and
CD4+ T cells, mast cells, eosinophils, and epithelial cells of
asthmatics in response to antigen, mitogen, histamine, and
serotonin. This cytokine induces chemotactic responses in T
cells, eosinophils, and monocytes via its receptor CD4 (Center et al,
1996). The best known function of IL-16 is the recruitment of
CD4-positive effector cells into in¯ammatory sites, as in asthma
(Laberge et al, 1997) and atopic dermatitis (Laberge et al, 1998).
Recent data show that human monocyte-derived DC produce IL-
16, but are also able to migrate along an IL-16 gradient (Kaser et al,
1999). We, therefore, wondered whether IL-16 would also exert
effects on the migratory capacity of DC in the skin.
MATERIALS AND METHODS
Mice BALB/C mice were purchased from Charles River (Sulzfeld,
Germany) and used at the age of 8±15 wk. CD4-knock-out mice,
originating from the laboratory of Dr. T.W. Mak, Toronto, ON,
Canada (Rahemtulla et al, 1991), were kindly provided by Dr. B.
Ludewig, ZuÈrich, CH.
Media and reagents for skin organ cultures Culture medium was
RPMI-1640 (Biochrom KG, Berlin, Germany) supplemented with 10%
fetal bovine serum (Biological Industries, Kibbutz Beit Haemek, Israel),
2 mM L-glutamine (Sebac, Stuben, Austria), 0.05 mM 2-mercaptoethanol
(Sigma, St Louis, MO) and 20 mg gentamycin per ml (Amimed AG,
Allschwil, CH). Recombinant human IL-16 was obtained from
Pharmingen (San Diego, CA). As human and mouse IL-16 are mutually
cross-reactive to a very high degree (Keane et al, 1998) we used the
human cytokine for both human and mouse experiments. Recombinant
murine TNF-a (speci®c activity 1.2 3 107 U per mg) was a generous
gift of Dr. G.R. Adolf (Bender, Vienna, Austria) and SLC/CCL21 was
from Peprotech (London, U.K.). The antibody against human IL-16
(14.1; Cruikshank et al, 1994) and the appropriate control antibody
(mouse IgG2a) were also from Pharmingen. A neutralizing polyclonal
antibody against TNF-a was purchased from Biosource (Camarillo, CA)
and a MoAb against TNF-a (V1q; Echtenacher et al, 1993) was a kind
gift of Dr. B. Echtenacher (Regensburg, Germany). Antibodies against
CD4 (GK1.5; Dialynas et al, 1983) and the isotype-matched control
(LO-DNP-11, rat IgG2b) were used as hybridoma supernatants.
Skin organ culture Ears from mice were disinfected in 70% ethanol
and separated into dorsal and ventral halves with forceps. The dorsal
halves (cartilage-free) were incubated in 24-well tissue culture plates (one
ear per well) as described (Larsen et al, 1990; Ortner et al, 1996). Before
the onset of culture the ears were rested at + 4°C for 28 h in an attempt
to attenuate endogenous cytokine production. Human skin explant
cultures were carried out as described before (Lenz et al, 1993; Pope et al,
1995). Split-thickness skin (0.3 mm) from corrective plastic surgery of
mammae and abdomina was trimmed to pieces with a punch (8 mm
diameter). Alternatively, epidermis and dermis were separated from each
other by means of the bacterial enzyme dispase (Kitano and Okado,
1983), and the dermis-free epidermal sheets were placed in culture.
Culture medium was supplemented with different concentrations of
cytokines. Whenever antibodies were used the skin explants were
preincubated with the MoAbs alone for 1±2 h. In the neutralization
assays IL-16 and MoAb 14.1 were preincubated in culture wells for 2 h
before skin explants were placed on to the culture medium. The skin
organ cultures were incubated for 48 h at 37°C. DC, which had
emigrated into the culture medium, could be identi®ed by their typical
``veiled'' appearance and were enumerated with the hemocytometer. For
each experimental condition six explants were pooled. Organ culture on
culture medium alone was used as a control. DC numbers from this
control were set equal to 100%. Each experimental condition was
expressed in percent of the control. This needed to be done to allow for
a better comparison of data from different experiments because the
absolute numbers of DC that migrated from the explants varied
considerably between different individual experiments. This approach
had been described previously (Randolph et al, 1998). All
experiments done were included into the analysis and the numbers
are indicated as ``n'' in the ®gure legends. Student's t test for paired
samples was applied to determine the signi®cance of the differences of
mean values.
Immunohistochemistry of emigrated DC Cytocentrifuge smears
were prepared from emigrated DC of murine skin organ cultures and
®xed in acetone. The phenotype of the cutaneous DC was determined
by staining with MoAb against invariant chain (clone IN-1, rat IgG2b;
Koch and HaÈmmerling, 1982), a maturation marker (clone 2A1, rat
IgG2a, from R.M. Steinman, New York, NY; Inaba et al, 1992;
Steinman et al, 1997) and the costimulatory molecule B7-2/CD86
(Pharmingen) for 30 min at 37°C. The subsequent incubations were
carried out with biotinylated anti-rat immunoglobulin, streptavidin±
Texas Red (both Amersham Life Science, Amersham, U.K.), rat
immunoglobulin for blocking residual free binding sites (Jackson
Immuno Research Laboratory, Avondale, PA) and anti-I-A/Ediverse
(clone 2G9, ¯uoresceinated, Pharmingen) for counterstaining the DC.
Intradermal administration of cytokines and MoAb Cyto-
kines and antibodies were diluted in phosphate-buffered saline/10% fetal
bovine serum and injected with 1 ml tuberculin syringes equipped with
a 30-gauge needle. Mice received 50 ml of cytokine dilution
intradermally into the pinna of one ear and the carrier protein alone into
the contralateral ear. After different time points (45 min, 1 h, and 24 h)
epidermal sheets were prepared. The skin was ¯oated dermal side down
on 0.5 M ammonium thiocyanate for 20 min at 37°C. The epidermis
was peeled off the dermis and both parts were cut into 5 3 5 mm pieces
and ®xed in acetone for 20 min. The sheets were stained with anti-I-
Ab,d (clone B21.2/TIB229, rat IgG2b, from R.M. Steinman, New York,
NY) followed by biotinylated anti-rat immunoglobulin and streptavidin-
¯uorescein isothiocyanate for 90 min at 37°C. The density of Langerhans
cells in the epidermis was counted under the microscope using 3 40
objective lenses and a calibrated grid (at least 20 ®elds). Student's t test
for paired samples was applied to determine differences and signi®cance
of the results.
Detection of IL-16 and its receptor CD4 in skin explants, TNF-a-
treated skin and contact allergen-treated skin To detect
endogenous IL-16 and its ligand CD4, we prepared epidermal and dermal
sheets from murine ear skin before and after culture and after intradermal
injection of TNF-a. Additionally, mouse ear skin was sensitized with
10 ml 1%-TNCB (2,4,6-trinitro-1-chlorobenzene, picryl-chloride, Kodak
Eastman, Rochester, NY) on the dorsal and ventral side. Five days later
the contralateral ear skin was challenged in the same way with 5 mL 1%-
TNCB and used for sheet preparation after the development of a contact
hypersensitivity reaction (24 h or 48 h later). Also sheets obtained 12 and
24 h after the ®rst picryl-chloride application (i.e., sensitization phase)
were analyzed. The sheets were stained for 90 min at 37°C with
antibodies against IL-16 (MoAb 14.1 and biotinylated polyclonal antibody
anti-mouse and anti-human IL-16, both from Pharmingen) or anti-CD4
(GK1.5), followed by biotinylated-second step antibodies and/or
streptavidin-¯uorescein isothiocyanate/±Texas Red and in some cases by
anti-I-A/Ediverse (clone 2G9, ¯uoresceinated). For the intracellular
detection of IL-16 the sheets were additionally permeabilized with 0.1%
saponin during the whole staining procedure.
Detection of IL-16 and CD4 on epidermal cells and emigrated
cutaneous DC Epidermal cells were isolated as described before
(Schuler and Steinman, 1985; Romani et al, 1997). After ®xation with
1% paraformaldehyde (PFA) and permeabilization with 0.1% saponin, the
DC were stained with anti-IL-16 (14.1), biotinylated anti-mouse
immunoglobulin and streptavidin±¯uorescein isothiocyanate for 30 min
on ice. Emigrated DC from mouse skin explant cultures were incubated
with anti-CD4 (GK1.5), biotinylated anti-rat immunoglobulin and
streptavidin±¯uorescein isothiocyanate for 30 min on ice. The cells were
analyzed by ¯ow cytometry. An additional way to detect small amounts
of surface antigen is complement-mediated lysis using speci®c MoAb
(Crowley et al, 1989). Epidermal cells were isolated and incubated for
1 h with anti-I-Ab,d (clone B21.2) as positive control, anti-CD4 (GK1.5)
and isotype-matched MoAb (LO-DNP11, rat IgG2b) and rabbit-low-tox
complement (Cedarlane, Ontario, Canada) for depleting Langerhans cells
expressing these antigens. The remaining cells were cultured in medium
supplemented with 5 ng per ml granulocyte-monocyte colony-
stimulating factor for 72 h at 37°C. The fully mature, and therefore
clearly recognizable ``veiled'' Langerhans cells, which had survived the
killing procedure, were counted in the hemocytometer. Additionally, in
one experiment we added anti-Thy-1.2 (TIB 99, clone HO-13.4, mouse
IgM) to the above described settings to deplete a large part of
keratinocytes and analyzed the number of surviving Langerhans cells by
¯ow cytometry immediately thereafter.
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RESULTS
IL-16 enhances the emigration of cutaneous DC in murine
and human skin explant cultures To investigate the
in¯uence of IL-16 on the migration of cutaneous DC we
cultured murine skin explants with graded concentrations of IL-
16 (0.01±10 ng per ml) and counted the emigrated DC in the
culture medium. Spontaneous emigration into culture medium in
the absence of exogenous cytokines was set equal to 100%.
Between 5000 and 20,000 DC emigrated from one whole skin
explant (i.e., one dorsal ear half) and between 10,000 and 35,000
Langerhans cells could be recovered from one cultured epidermal
explant (i.e., epidermal sheet from one dorsal ear half). Each
experimental condition was set in relation to and expressed in
percent of the control. Even very low amounts of IL-16 (0.01 ng
per ml) enhanced the migration rate up to 126%. Intermediate
concentrations (0.1±2 ng per ml) increased migration to 128±136%
and the high doses (5 and 10 ng per ml) had weaker effects on
cutaneous DC (Fig 1A). Data for 1 ng per ml (where most
experiments were done) were highly signi®cant (136 6 29%,
n = 37, p < 0.0001, range: 77±203%) when compared with the
spontaneous emigration in the absence of exogenously added
cytokines. To set these values in relation to published data (Saeki et
al, 1999) we also added the chemokine SLC/CLL21 (10 ng per ml)
to the explants. We could observe a similar enhancement (139%) of
the DC emigration rate. In time course experiments we noted that
IL-16 is already operative in the initial stage of migration: already
after an overnight and a 24 h whole skin organ culture the numbers
of emigrated DC were increased in response to IL-16 (Table I). In
cultures of epidermal sheets we could observe a migration-
promoting effect of IL-16 similar to the whole skin explants, but
less prominent (Fig 1B, for 1 ng per ml: 124 6 19%, n = 10, p
< 0.01, range: 101±169%). To con®rm the speci®city of cytokine
action, a neutralizing MoAb against IL-16 (14.1) was added into the
skin explant cultures. Anti-IL-16 (10 mg per ml) clearly abrogated
the migration-promoting effect of IL-16 (1 ng per ml) in cultures
of both whole skin and epidermal sheets (Fig 1C).
These ®ndings were also reproduced in human whole skin
explant cultures. There, between 10,000 and 35,000 DC emigrated
per one 8 mm punch biopsy (equivalent to an area of 0.5 cm2).
Different concentrations of IL-16 (0.1±5 ng per ml) increased the
emigration of human cutaneous DC (Fig 1D). In contrast to the
murine skin cultures, however, higher concentrations of IL-16 (2±
5 ng per ml) were needed for maximal induction of emigration (for
2 ng per ml: 141 6 26%, n = 5, p < 0.05, range: 113±181%).
Cultures of dispase-separated epidermal sheets were not done with
human skin. It should be mentioned, however, that the emigrant
DC recovered from the human whole skin explants consisted
mainly of Langerhans cells as de®ned by Lag/Langerin (Kashihara et
al, 1986; Valladeau et al, 2000) staining (not shown). Semithin
sections of plastic embedded explants showed the reason for the
pronounced paucity of dermal DC in these experiments: the split-
thickness dermatome specimens were so thin that only very little
dermis still adhered to the epidermis (not shown).
Figure 1. IL-16 enhances the emigration of cutaneous DC in murine and human skin explant cultures. Skin explants were placed on to
medium with or without IL-16 in different concentrations or antibodies and the emigrated DC were counted in the medium after a 48 h culture.
Spontaneous emigration into culture medium in the absence of exogenous cytokines was set equal to 100% (horizontal line). (A) IL-16 (0.01±10 ng per
ml) added to the murine whole skin explant cultures increased the emigration rate in a similar way to SLC (10 ng per ml). (B) In murine epidermal
sheet cultures IL-16 (0.01±10 ng per ml) induced emigration of Langerhans cells but to a lesser extent than in the whole skin explants. (C) Anti-IL-16
MoAb 14.1 (10 mg per ml, open bars) neutralized the IL-16-enhanced migration (1 ng per ml) in whole skin and epidermal sheet cultures in contrast to
an isotype-matched control antibody (closed bars). (D) IL-16 added to the human skin cultures in graded concentrations (0.1±5 ng per ml) increased the
emigration rate (n = 5). n = number of individual experiments; results are expressed as mean 6 SD, *p < 0.05, **p < 0.01, ***p < 0.001.
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In contrast to explant cultures, intradermally injected IL-16
does not induce emigration of Langerhans cells It has
previously been shown that in¯ammatory cytokines can decrease
Langerhans cell numbers when injected intradermally
(Cumberbatch et al, 1997). We wondered whether IL-16 had a
similar effect on the Langerhans cell density. Different
concentrations of IL-16 (1, 10, 25 ng) were injected into the
dermis of mouse ears. After 45 min, 1 and 24 h the epidermis was
stained for MHC class II and Langerhans cells were counted under
the microscope. IL-16 had no in¯uence on the number of
Langerhans cells at all concentrations used and at the different time
points (Table II). In contrast, intradermal application of 40 ng of
TNF-a caused a reduction in the density of Langerhans cells of 13±
33% after 24 h (Fig 2; n = 4, p < 0.02). The combined injection of
MoAb 14.1 against IL-16 (10±50 mg per ml) and 40 ng of TNF-a
led to an attenuation of the TNF-a-induced emigration so that the
Langerhans cell numbers in the epidermal sheets were only
decreased by 8±10% (Fig 2; n = 3, p < 0.02). By immuno-
¯uorescence no differences between IL-16-injected (Fig 3b) and
control skin (carrier protein injections, Fig 3a) became obvious
with regard to the density and morphology of Langerhans cells. In
contrast, after injection of TNF-a (Fig 3d), the density of
Langerhans cells was decreased and the Langerhans cells seemed
activated when compared with the control (Fig 3c) as judged by
their enlarged cell bodies.
TNF-a and IL-16 cooperate in the emigration process in
murine skin explant cultures In previous reports (Stoitzner
et al, 1999; Cumberbatch et al, 1999) it has been shown that TNF-
a has a migration-promoting effect on cutaneous DC at low
concentrations and a migration-inhibiting effect at high
concentrations. Therefore, we wondered whether TNF-a and
IL-16 would cooperate in the induction and regulation of
migration. Simultaneously added IL-16 could not further modify
the TNF-a-induced/inhibited emigration in the murine skin
explant cultures (not shown). Combinations of TNF-a (50 U per
ml) and IL-16 (1 ng per ml) with their reciprocal neutralizing
antibodies, however, showed a clear interdependence of the two
cytokines. A preincubation of skin explants with the MoAb against
IL-16 (14.1, 10 mg per ml) could abrogate the migration-
promoting effect of low-dose TNF-a indicating the in¯uence of
endogenous IL-16 on the emigration (Table III, Fig 4; n = 3, p
< 0.05). Conversely, the preincubation with two different
antibodies against TNF-a (polyclonal antibodies neutralizing
300 U TNF-a per ml, MoAb V1q 33% vol/vol) or a prior
intraperitoneal injection of 1.5 ml V1q led to an inhibition of the
IL-16-enhanced migration (Table III, Fig 4; n = 5, p < 0.05).
IL-16-positive cells are detectable in the murine
dermis Given the effects of IL-16 on DC migration, we asked,
whether endogenous IL-16 is detectable in the skin and possibly
upregulated during skin explant culture, after contact allergen
application or intradermal injection of TNF-a. By immuno-
¯uorescence we were unable to stain IL-16 in freshly isolated
Langerhans cells and in situ in epidermal sheets of fresh, cultured,
TNF-a-treated skin and contact allergen-treated skin. In contrast,
IL-16-positive cells were readily visible in the dermis of untreated
skin (Fig 5a). During skin explant culture (Fig 5b) and during a
contact hypersensitivity response (Fig 5c) more, and more strongly
stained IL-16-positive cells appeared in the dermal compartment.
Furthermore, intradermal injection of TNF-a also led to a distinct
upregulation of IL-16 production in dermal cells (Fig 5d); control
injection of carrier protein alone did not do so (Fig 5e). IL-16-
positive cells also appeared in the sensitization phase of contact
Table II. Intradermally injected IL-16 does not induce
emigration of Langerhans cells
Injection of
Time after injection
45 min 1 h 24 h
IL-16 1 ng ± 106% ±
IL-16 10 ng 104%a 99% 101%
IL-16 25 ng ± 118% ±
No cytokine, carrier
protein only
100% 100% 100%
aLangerhans cell density in epidermal sheets compared with injections of carrier-
protein (set as 100%); n = 3.
Table I. Kinetics of the migration-enhancing effect of IL-16
Overnight culturea 24 h culturea 48 h standard culturea
DC per one
ear explantb
Relative cell
numbersc
DC per one
ear explant
Relative cell
numbers
DC per one
ear explant
Relative cell
numbers
Experiment no. 1
Medium only 3210 100% 3405 100% 9740 100%
IL-16 100 pg per ml 2250 70% 5365 158% 10850 112%
IL-16 1 ng per ml 2750 86% 4750 140% 14575 149%
Experiment no. 2
Medium only 1000 100% 1665 100% 3955 100%
IL-16 100 pg per ml 1275 128% 2325 140% 3500 88%
IL-16 1 ng per ml 1065 107% 1065 64% 4935 125%
Experiment no. 3
Medium only 1100 100% 4125 100% 5280 100%
IL-16 100 pg per ml 1135 103% 3295 80% 7400 140%
IL-16 1 ng per ml 1835 167% 3535 86% 7695 146%
Experiment no. 4
Medium only 1405 100% 2520 100% 6745 100%
IL-16 100 pg per ml 2210 157% 3795 151% 7280 108%
IL-16 1 ng per ml 2155 153% 3225 128% 7695 140%
aMouse whole skin explants were cultured for the indicated times. Skin explants were removed and the emigrated cells were further cultured in the presence of
granulocyte-monocyte colony-stimulating factor up to 48 h. This needed to be done because after the short culture periods DC cannot be reliably identi®ed in the hemo-
cytometer. Note that, as expected, numbers of emigrant cells increase with time and, more importantly, IL-16 augments these numbers in most experiments also during
short-term cultures.
bAbsolute number of DC emigrated per one explant.
cRelative numbers of emigrated DC in relation to ``medium only'' controls that were set equal to 100%.
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hypersensitivity, i.e., 12±24 h after application of a contact
sensitizer (not shown). To get a clue as to which dermal cell type
can produce the IL-16, dermal sheets were counterstained with
anti-MHC II. All IL-16-positive cells were clearly MHC class II-
negative (Fig 5f), ruling out DC as the source of IL-16.
The migration-promoting effect of IL-16 is only partially
dependent on CD4 ligation in murine skin explant
cultures As the known receptor for IL-16 is the CD4
molecule, we tried to block the interaction with a MoAb against
CD4 (GK1.5) to prove the speci®city of the IL-16/CD4
interaction. Preincubation of whole skin explants with MoAb
GK1.5 (33% vol/vol) did neutralize the IL-16-induced emigration
in most experiments (Fig 6; n = 7, p < 0.001). Surprisingly, in
cultures of epidermis only we were unable to block the IL-16 effect
(Fig 6; n = 9). To con®rm that the IL-16 effect on Langerhans
cells was not CD4 dependent, we carried out skin organ cultures
with CD4-de®cient mice. Also, increased DC migration occurred
after addition of IL-16 to whole skin cultures (Fig 6; n = 2) and
epidermal sheet cultures (Fig 6; n = 5, p < 0.01). Underscoring
these results, immuno¯uorescence staining of wild-type epidermal
sheets from fresh and cultured skin with anti-CD4 was repeatedly
negative. In addition, Langerhans cells that had ``crawled out'' from
epidermal explants were also negative for CD4 in ¯uorescence-
activated cell sorter analyses (Fig 7). By complement-mediated lysis
we tried to detect possible minute amounts of CD4 molecules on
the surface of Langerhans cells in freshly prepared epidermal cell
suspensions. In contrast to the observed speci®c killing by the
MoAb against MHC class II (B21.2), anti-CD4 (GK1.5) caused no
changes in the percentage of Langerhans cells in the epidermal cell
suspensions (data not shown). These ®ndings con®rm that murine
Langerhans cells express no CD4, emphasizing earlier data of
Crowley et al (1989). In contrast, in dermal sheets CD4-positive
cells were readily visible by immuno¯uorescence, likely
representing CD4+ T cells, monocytes/macrophages and possibly
dermal DC. A CD4-positive population was also present in cells
emigrated from whole skin explants (data not shown).
DISCUSSION
The migration of cutaneous DC after antigenic challenge is
initiated by different in¯ammatory mediators, such as TNF-a, IL-
1b (Cumberbatch et al, 1997; Stoitzner et al, 1999), and modulated
by anti-in¯ammatory cytokines, such as IL-10 (Wang et al, 1999)
and by diverse chemokines, such as MIP-3b (Kellermann et al,
1999) and SLC (Saeki et al, 1999). In this report we demonstrate
that IL-16, a cytokine hitherto unrecognized in that regard, is
critically involved in the emigration process of cutaneous DC.
Exogenous IL-16 enhanced the emigration of DC out of human
and murine skin explants. The IL-16-induced migration was
abolished by the addition of an anti-IL-16 MoAb underscoring the
speci®city of cytokine action. By immunohistochemistry we found
increased numbers of IL-16-reactive cells in the dermis under
circumstances of enhanced DC migration suggesting an in vivo role
for this cytokine.
Quality of the IL-16 effect To investigate the mode of action,
we injected different concentrations of IL-16 intradermally into
mouse ears. Surprisingly, at no time point we observed a decrease
in the Langerhans cell density as seen in TNF-a-injected skin. This
led to the conclusion that IL-16 can induce emigration of
cutaneous DC ex vivo in the skin organ cultures only and not
Figure 3. In contrast to TNF-a, IL-16 does
not change the morphology and density of
Langerhans cells in epidermal sheets.
Epidermal sheets were prepared 24 h after
intradermal injection and were immunostained for
Langerhans cells using anti-MHC class II MoAb
B21-2. No differences in the morphology and
density of Langerhans cells became evident
between sheets from IL-16-injected (10 ng) ears
(b) and the sheets from the contralateral ear
injected with carrier protein only (a). In contrast,
40 ng of TNF-a (d) led to an activation and a
reduced density of the remaining Langerhans cells
as compared with the control ear (c). Scale
bar: 50 mm.
Figure 2. Anti-IL-16 MoAb attenuates TNF-a-induced emigra-
tion of Langerhans cells in vivo. IL-16, TNF-a, anti-IL-16, or carrier
protein (control) were injected intradermally into mouse ears and
numbers of remaining Langerhans cells were determined in epidermal
sheets 24 h later. In contrast to the injection of 10 ng IL-16 (n = 3,
n.s.), 40 ng TNF-a led to a clear-cut decrease in the cell number 24 h
after injection (n = 4, p < 0.02). The MoAb against IL-16 (14.1; 10±
50 mg per ml) injected simultaneously with TNF-a attenuated the
TNF-a-induced emigration of Langerhans cells (n = 3, p < 0.02). Open
bars indicate corresponding control injections with carrier protein,
n = number of individual experiments; results are expressed as
mean 6 SD.
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in vivo after intradermal injections. We speculate that intradermally
injected IL-16 cannot exert its migration-promoting effect because
it cannot provide the necessary in¯ammatory stimulus given in the
explant cultures by the release of in¯ammatory cytokines such as
TNF-a which is needed for mobilizing the Langerhans cells within
the epidermis. So, in contrast to TNF-a (Jakob and Udey, 1998),
IL-16 cannot break up E-cadherin bonds and endow Langerhans
cells with enzymatic properties for penetrating the basement
membrane by upregulating matrix metalloproteinases. We
conclude that IL-16 is not an in¯ammatory mediator in the
emigration process like TNF-a (Cumberbatch et al, 1994; Stoitzner
et al, 1999). Rather, IL-16 acts in a chemotactic manner by
enhancing the emigration started by the TNF-a-induced
detachment of DC from neighboring keratinocytes. The IL-16
effect is dependent on the presence of in¯ammatory cytokines in
the skin: we ®nd here that TNF-a upregulates IL-16 in the dermis.
Chemotaxis as the mode of action is supported by the fact that the
effects were observed in skin explant cultures, which may be
regarded as ``ex vivo chemotaxis assays'' (Kellermann et al, 1999). A
further observation in vivo underscores this conclusion. The
neutralization of endogenous IL-16 by intradermally applied
antibodies inhibited TNF-a-induced Langerhans cell emigration.
These data are consistent with the ®ndings of other groups
demonstrating a chemotactic effect of IL-16 on all CD4-positive
cells (Center et al, 1996) and, more recently, also on monocyte-
derived immature DC (Kaser et al, 1999).
Interactions of IL-16 with in¯ammatory cytokines We tried
to determine further the interdependence of IL-16 and TNF-a
during the emigration process of cutaneous DC out of the skin. We
have previously reported that TNF-a at low concentrations (50 U
per ml) has a migration-promoting effect and at higher
concentrations (500±5000 U per ml) a migration-inhibiting effect
on DC in skin explants (Stoitzner et al, 1999). When added
simultaneously, IL-16 could not further modify these migration-
promoting and migration-inhibiting effects of TNF-a. Never-
theless, a MoAb against IL-16 could abrogate the TNF-a-induced
emigration in the skin explant cultures. When the MoAb against
IL-16 was injected intradermally together with TNF-a, the
TNF-a-induced emigration of Langerhans cells in vivo was also
reduced. These data suggest that TNF-a by itself does not suf®ce to
ensure optimal migration. Reciprocally, two different antibodies
against TNF-a clearly abolished the chemotactic effect of IL-16 in
skin explant cultures. Furthermore, intradermal injection of
TNF-a led to an upregulation of the IL-16 production the
dermis. Taken together, these results suggest that with the help of
an in¯ammatory stimulus, such as TNF-a, Langerhans cells can
detach from the surrounding keratinocytes (Tang et al, 1993) and
start to migrate out of the epidermis. TNF-a also induces the
endogenous IL-16 production (presumably by dermal T cells, mast
cells, etc.) which enhances and guides, chemotactically, the
ongoing emigration of cutaneous DC. Such in¯ammatory
situations occur in skin organ cultures or contact hypersensitivity
reactions.
In vivo relevance of IL-16 in the skin To con®rm further the
proposed role for IL-16 in the skin immune system, we investigated
the presence of IL-16 in murine skin. By immuno¯uorescence
staining we were unable to ®nd any IL-16 in the murine epidermis.
In the dermis, however, IL-16-positive cells became visible. This
staining pattern became more pronounced during skin organ
culture, or contact hypersensitivity reactions and after intradermal
injection of TNF-a in that more dermal cells produced IL-16. This
suggests the involvement of endogenous IL-16 on emigrating
cutaneous DC in the skin explant cultures. Similar results were
obtained by other groups, which detected IL-16 in human skin.
Table III. Interdependence of TNF-a and IL-16 in the migration process of cutaneous DC
Cytokineb
Anticytokine
antibodies
Absolute numbers of DC emigrated from 48 h cultured murine whole skin explant culturesa
A B
IL-16
C
IL-16
anti-IL-16
D
IL-16
anti-TNF-a
E
TNF-a
F
TNF-a
anti-IL-16
Experiment no.
1 16,680 22,310 10,645
2 17,795 21,445 13,985 22,140 16,945
3 8250 8620 2590
4 11,010 14,085 7645
5 10,270 12,015 12,790 13,270 9225
6 13,535 18,035 12,515
7 18,100 28,088 11,960
8 6095 7800 4820
aMurine skin explants were placed on to medium with IL-16 or TNF-a plus the respective contrary antibodies and the emigrated DC were counted in the medium after
a 48 h culture. Note that anti-TNF-a neutralizes IL-16-induced migration in four of ®ve experiments (columns A, B, D). Reciprocally, anti-IL-16 abrogates TNF-a-in-
duced migration in three experiments (columns A, E, F). Values indicate the absolute numbers of DC emigrated per one ear skin explant.
bIL-16 was used at a concentration of 1 ng per ml; TNF-a at 50 U per ml (see also Fig 4).
Figure 4. Interdependence of TNF-a and IL-16 in the migration
process of cutaneous DC. Skin explants were placed on to medium
with IL-16 or TNF-a plus the respective contrary antibodies and the
emigrated DC were counted in the medium after a 48 h culture.
Spontaneous emigration into culture medium was set equal to 100%
(horizontal line). The MoAb against IL-16 (14.1; 10 mg per ml) could
abrogate the TNF-a (50 U per ml) -induced emigration (n = 3, p
< 0.05). Conversely, the antibodies against TNF-a (polyclonal antibodies
neutralizing 300 U per ml TNF-a, MoAb V1q 33% vol/vol) could
abolish the chemoattractant effect of IL-16 (1 ng per ml) (n = 5, p
< 0.05). n = number of individual experiments; results are expressed as
mean 6 SD (see also Table III).
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Laberge et al (1998) could detect mRNA for IL-16 in normal skin
biopsy specimens pointing at low constitutive IL-16 gene
expression for immune surveillance under normal conditions. In
acute in¯amed skin lesions more IL-16 mRNA+ cells associated
with CD4+ T cell in®ltrate were observed in the epidermis and the
dermis. Another report by Kaser et al (1999) found IL-16-positive
cells in the epidermis of serial tissue sections of normal human skin
indicating IL-16 production by keratinocytes. Different to our
®ndings in mouse skin, IL-16 appears to be expressed in the human
epidermis. This may be due to differences between the species and
it might explain the need of higher concentrations of IL-16 in the
human skin explant cultures. The functional importance of IL-16
for the migration of cutaneous DC is suggested by recent data from
Yoshimoto et al (2000). They demonstrated that IL-16 production
is upregulated in a delayed-type hypersensitivity situation induced
by injecting methylated bovine serum albumin into mouse footpads
and that the delayed-type hypersensitivity response is inhibited by
prior injection of anti-IL-16 MoAb. Clearly, migrating cutaneous
DC are involved in the delayed-type hypersensitivity reaction.
Thus, our data suggest the novel aspect that locally secreted IL-16,
provided by activated T cells, eosinophils (Center et al, 1996), or
mast cells (Laberge et al, 1999), might serve as a chemotactic factor
attracting the emigrating DC into the collagen matrix of the
dermis.
The binding of IL-16 to its receptor The receptor for IL-16 is
CD4 (Center et al, 1996). Surprisingly, in cultures of murine
epidermal sheets we were unable to block the IL-16-induced
migration of Langerhans cells by anti-CD4 antibody. Therefore, we
tried to detect CD4 molecules on cutaneous DC and especially on
Langerhans cells. Unlike on human Langerhans cells (De Pan®lis
et al, 1988), human blood DC (O'Doherty et al, 1993) and mouse
spleen DC (McLellan and KaÈmpgen, 2000; Vremec et al, 2000),
CD4 expression has not been unequivocally shown on murine
cutaneous DC. We carried out immuno¯uorescence staining
experiments with epidermal sheets and isolated Langerhans cells.
Neither in epidermal skin explants prior to and after culture nor on
emigrated Langerhans cells could we prove CD4 expression.
Underscoring this, Crowley et al (1989) demonstrated that murine
Langerhans cells isolated and cultured for 1 d were clearly negative
for CD4 when tested with the MoAb GK1.5. As minute but
functional levels of CD4 on Langerhans cells can never be formally
excluded in immunohistochemical analyses we decided to use
CD4-de®cient mice. Also, in the total absence of CD4 molecules,
IL-16 could still attract Langerhans cells from epidermal explants.
From these data we conclude that the ligand for IL-16 in murine
epidermis cannot be CD4 and that another ligand for IL-16 may
Figure 5. IL-16-positive MHC class II-negative cells are detectable in the dermis. The dermal and epidermal part of skin explants before and
after culture, during a contact hypersensitivity response and after intradermal injection of TNF-a or carrier protein were stained with a MoAb against
IL-16 (14.1; green ¯uorescence in (a±e), red ¯uorescence in f). In the dermis of fresh murine skin (a) few IL-16-positive cells were visible. Their
numbers increased during skin explant culture (b), in a contact hypersensitivity response (c) and after intradermal injection of TNF-a (d) in contrast to
injection of carrier protein (control) (e). Double-labeling showed that the IL-16-positive cells (red ¯uorescence) in the dermis were clearly MHC class II
negative (green ¯uorescence) (f). Scale bar: 50 mm.
Figure 6. The effect of IL-16 depends only partially on the CD4
ligation. Murine skin explants were placed on to medium with IL-16
alone or in combination with a MoAb against CD4 (GK1.5) and the
emigrated DC were counted in the medium after a 48 h culture.
Spontaneous emigration into culture medium was set equal to 100%
(horizontal line). Preincubation of whole skin explants (closed bars) with
anti-CD4 (33% vol/vol) resulted in the abrogation of IL-16-induced
migration (n = 7, p < 0.001). This is in contrast to cultures of epidermal
sheets (open bars) in which no blocking of the IL-16 effect was observed
(n = 9, n.s.). DC of CD4-de®cient mice (hatched bars) did emigrate in
increased numbers out of whole skin explants (n = 2, n.s.) and epidermal
sheet cultures in response to IL-16 (n = 5, p < 0.01). n = number of
individual experiments; results are expressed as mean 6 SD.
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exist on Langerhans cells of murine epidermis. This is further
emphasized by the recent demonstration that murine blood-derived
monocytes of CD4-de®cient mice migrate in response to IL-16 in
chemotaxis assays (Mathy et al, 2000). One possible candidate for an
alternative receptor is the lymphocyte activation antigen (LAG) -3,
which has high homology to the CD4 molecule (Triebel et al,
1990) and is able to block the CD4/MHC class II interaction
(Huard et al, 1995). Therefore, it would be interesting to use LAG-
3-de®cient mice for skin explant cultures (Miyazaki et al, 1996).
Other candidates are chemokine receptors, such as CCR5 and
CXCR4, which are known to act as co-receptors for HIV-1
together with CD4 on human Langerhans cells (Granelli-Piperno
et al, 1996). Recently, the involvement of chemokine receptors in
the chemotactic effect of IL-16 was reported by Mashikian et al
(1999). They found that the preincubation of human T cells with
MIP-1b, which binds to CCR5, completely blocked the IL-16-
induced chemotaxis.
In conclusion, our data show that IL-16 is a novel and additional
mediator regulating the emigration process of cutaneous DC. In a
simpli®ed scenario one could envisage that the in¯ammatory
cytokines TNF-a and IL-1b loosen the molecular connections of
DC to their surroundings (e.g., E-cadherin), upregulate necessary
enzymes on the DC (e.g., matrix metalloproteinases), and also
induce the production of chemotactically active mediators (MIP-
3b, SLC, IL-16) that attract and guide the migrating DC into the
lymphatic vessels and further on into the lymph nodes. The skin
explant culture method can be used to de®ne further the in¯uence
of these cytokines in the migration of DC and has the additional
option to be used for chemokines as an ``ex vivo chemotaxis assay''
(Kellermann et al, 1999). IL-16 is gaining increasing interest
because of its involvement in several different diseases such as
allergic asthma (Mashikian et al, 1998), atopic dermatitis (Laberge et
al, 1998), and HIV replication (Amiel et al, 1999). DC presumably
play important parts in these diseases. Therefore, further investi-
gations seem desirable.
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